Big picture - Why invest in Alliance Pharma plc
Alliance Pharma plc Snapshot
Our vision guides our business by describing what we need to do to become a great company and sustain our growth.
"Breathing life into medicines"
by attending to the 4 P's below:
Acquire a portfolio of good products that will continue to meet demonstrable medical needs and steady, sustainable sales. Selectively develop them at low risk and extract additional value from them.
Cultivate a network of licensors, suppliers and customers to create lasting mutual value.
Inspire our people to be the best they can be.
Maximise long term return for our shareholders.
Our values shape our actions and describe how we behave in the world
Delivery over many dimensions: quality, timeliness, outputs to name but a few.
Inventiveness, creativity, and the setting of challenging targets are vital. Balanced against this is realism in the projects we select and the targets we set. This way we minimise risks and going down blind alleys.
Accepting accountability, at both the personal and team levels. The chain is only as strong as the weakest link.
We thrive on trust, honesty and delivering on our promises.
We bring into the business high calibre people who either possess the necessary skills or have the capability of gaining them. We will provide an environment that encourages continuous development.
Our capability to be creative, to grasp opportunities and successfully develop them is fundamental to our growth. Managing your job as if it was your own business is the true meaning of entrepreneurship.
Alliance focuses on specialist medicines and related products, in particular those driven by prescription or professional recommendation and where revenues are sustainable.
The company believes it can continue to grow successfully long term by pursuing its strategy of:
- Acquisition and in-licensing of established products and niche speciality brands.
- Selectively extracting additional value from its assets as a result of its lean business model and unique set of skills. Skills such as lifecycle management, reclassification, extending product lines and markets, commercial deal making and partnering.
- Selectively building brands and opening up new markets.
We are particularly interested in products and businesses in the following areas:
- Established products
- Dermatology & Oncology
- Other specialised hospital products
The established products business is our core business. We acquire good, substantial products that continue to meet medical needs. In the UK we have become a leader in the acquisition and management of established products. These products typically grow modestly without active promotion as market demand increases due to changing demographics. The risk of attrition due to competition has usually already occurred or is limited for these products. The value of these product assets is sustained through our ability to keep them up to date and maintain continuity of supply.
Having acquired these products’ our team has a unique collection of skills to selectively make medicines better and breathe new life into them. BUCCASTEM, DELTACORTRIL and NU-SEALS are just some of the products that have benefitted from this extra treatment and additional value has been extracted.
Depending on the elements of the marketing mix required these products may find their way into our related business units or into partnerships with other players. Whatever the case our aim is to maximise the value of the acquired assets for our shareholders.
Low and standard dose aspirin with protective coat to help protect against GI side effects of aspirin, low dose is used to prevent heart attacks and ischaemic strokes ,Standard dose used for all aspirin indications except acute pain relief.
Gastro-resistant tablets. Used for a wide range of disorders in which systemic corticosteroids are indicated, including allergies, arteritis, rheumatic fever, rheumatic disorders, autoimmune disorders etc.
Caps containing 24 essential vits and mins for use in patients with nutritional deficits, for example in organic diseases such as AIDS, or as a nutritional adjunct following chemotherapy or radiation treatment in conditions where vitamin/mineral absorption is affected such as bowel disease or in the presence of food intolerance.
VITAMIN E deficiency in malabsorption disorders. It is the only UK licensed liquid formulation treatment for the correction of Vitamin E malabsorption in conditions such as including Cystic Fibrosis (CF, primary indication) and chronic cholestasis. The active ingredient is tocopherol acetate, a synthetic form of vitamin E.
For a full list of products please click here...
The Dermatology Business Unit has evolved out of our core established products business and has allowed Alliance to broaden its portfolio through the acquisition of selected dermatological products. These include treatments for eczema, psoriasis, ichthyosis, acne, warts and irritated skin.
The acquisition and subsequent promotion of the Hydromol range has proved particularly successful with sales tripling over the last 4 years. The HYDROMOL Range consists of HYDROMOL Bath and Shower Emollient, HYDROMOL Cream, HYDROMOL Ointment and HYDROMOL Intensive.
Further information can be found on the HYDROMOL website www.hydromol.co.uk
The addition of TIMODINE to the dermatology business in 2009 is an example of Alliance’s continued ambition to expand its portfolio and establish itself in the dermatology market.
Alliance aims to grow its business rapidly through International expansion. We are currently in the process of establishing affiliates throughout Europe. These affiliates will be growing their businesses through the acquisition and licensing of mature pharmaceutical products, medical devices, OTCs and the marketing of those products. Key international markets are China, the Republic of Ireland, France and Germany.
In addition we sell our products in over 25 territories. Key international brands are NU-SEALS and FORCEVAL. The International business has grown historically through acquisitions of business and products and the development of a network of distributors.
With a specialist business unit focused on the promotion and supply of specialist secondary care (hospital) medicines, Alliance provides full and direct key account coverage to hospitals across the UK, specifically in the therapeutic areas of urology and oncology.
These products include the BCG immunotherapy brand IMMUCYST 81MG, which is for the treatment of non invasive bladder cancer. Non muscle invasive bladder cancer accounts for 70% of diagnosed bladder cancer in the UK.
Other products include GELCLAIR, for the management of chemotherapy and radiotherapy induced oral mucositis, a painful and debilitating side effect of cancer treatments.
Further information can be found on the GELCLAIR website www.gelclair.co.uk
Andrew joined the Board of Alliance in 2006. He has held various senior positions in the pharmaceutical industry in the UK and USA having been managing director and senior vice-president of SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), chief executive of Cerebrus plc until its sale and president international medical marketing services with Parexel International. Andrew is a founder of Navitas BioPharma Consulting. He graduated in Natural Sciences from the University of Cambridge.
Tony joined Alliance in 1998. He has had around 30 years experience in the pharmaceutical and healthcare industries, with positions at Leo Pharma, Glaxo Wellcome (now GlaxoSmithKline) and Getinge Industrier AB. His senior management experience includes positions in the UK and internationally. Tony graduated in Physiology, has an MBA from Warwick and is a Chartered Marketer.
Thomas joined the board of Alliance as a non-executive director on 3 March 2009. He is a partner at MVM Life Science Partners LLP, a life science venture capital fund. He has been an active investor in life sciences since joining MVM in 2002. Before joining MVM, Thomas worked at PricewaterhouseCoopers LLP where he qualified as a Chartered Accountant. Thomas graduated in Molecular and Cellular Biochemistry from the University of Oxford in 1998.
Nigel joined the Board of Alliance in January 2015. He is Chief Executive of Procserve Holdings Limited, a leading company in enabling secure transactions online. He has also held senior positions at Micro Focus International plc, Nokia, Symbian Software Ltd, Tertio Telecoms Limited, Cable and Wireless plc, Glasgow Royal Infirmary NHS Trust and BT plc. Nigel is a Non Executive Director of Anite plc. He graduated in Geography from the University of Cambridge.
John founded Alliance in 1996. He gained multi-disciplinary experience in the pharmaceutical industry over 30 years. John held various senior roles at Sandoz (now Novartis AG) as director of finance and administration and deputy managing director. John has a BSc (Pharmacy) and an MSc (Finance) from the London Business School.
Peter joined the board of Alliance in February 2010 following the acquisition of Cambridge Laboratories, where he spent five years, latterly as UK Commercial Director. He is a board Member of the Association of the British Pharmaceutical Industry ("ABPI") and is chairman of the ABPI Small Companies Forum. Prior to joining Cambridge Laboratories, Peter spent six years at GlaxoSmithKline. He holds an honours degree in Pharmacology from the University of Edinburgh.
David joined the Board of alliance in April 2014. He is Chief Financial Officer and Chief Business Officer of Biotie Therapies Inc., a drug development copany quoted in Helsinki on the NASDAQ QMX market. He has previously held senior financial positions with Jazz Pharmaceuticals Limited, EUSA Pharma Inc., and Cephalon Inc. David qualified as a Chartered Accountant with PricewaterhouseCoopers after graduating in chemistry at the University of Oxford.
Taken from company website 22.07.15
Alliance Pharma plc
Wiltshire SN15 2BB
Tel: +44 (0)1249 466966
Fax: +44 (0)1249 466977
Email: [email protected]
Investor Relations: [email protected]
Business Development: [email protected]
International: [email protected]
Alliance Pharma plc
Registered Office as above
Registered in England
Company Number 04241478
Alliance Pharmaceuticals Limited
Registered Office as above
Registered in England
Company Number 03250064
Broker & Nominated Advisor: Numis Securities
Bank: Lloyds Bank and Royal Bank of Scotland
Auditor: Grant Thornton UK LLP
Financial PR: Buchanan Communications
34 Beckenham Road